SCHEMBL5329435

SCHEMBL5329435

NC(=O)OC(CCCCC(=O)c1cc2c(c(S(N)(=O)=O)c1)CCC2)Cc1ccccc1Cl

nearest known ligand 0.35

Predicted protein targets (top 19)

geneUniProtsupporting neighboursconfidence
P2RX4 Q99571 12/20 0.35
CA1 P00915 5/20 0.35
CA2 P00918 5/20 0.35
CA7 P43166 3/20 0.35
CA13 Q8N1Q1 3/20 0.35
CA12 O43570 2/20 0.35
CA3 P07451 2/20 0.35
CA4 P22748 2/20 0.35
CA6 P23280 2/20 0.35
CA5A P35218 2/20 0.35
CA9 Q16790 2/20 0.35
CA14 Q9ULX7 2/20 0.35
CA5B Q9Y2D0 2/20 0.35
NPC1 O15118 2/20 0.33
RAB9A P51151 2/20 0.33
NLRP3 Q96P20 1/20 0.32
HTT P42858 1/20 0.31
SMN1; SMN2 Q16637 1/20 0.31
L3MBTL1 Q9Y468 1/20 0.31

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL5328208 0.80 CA1 (0.35) P2RX4CA1CA2CA7CA13
SCHEMBL14513391 0.78 CA1 (0.38) P2RX4CA1CA2CA7CA13
Hydrochloric Acid SCHEMBL5360907 0.78 CA1 (0.37) P2RX4CA1CA2CA7CA13
SCHEMBL5577163 0.77 CA1 (0.37) P2RX4CA1CA2CA7CA13
SCHEMBL5576878 0.75 CA12 (0.35) P2RX4CA1CA2CA7CA13
SCHEMBL5310504 0.73 NPC1 (0.37) CA1CA2CA7CA13CA12
SCHEMBL5328513 0.70 NPC1 (0.35) CA1CA2CA7CA13CA12
SCHEMBL14513390 0.69 SLC2A1 (0.46) CA1CA2CA12CA5ACA9
SCHEMBL5329224 0.69 SMN1; SMN2 (0.33) P2RX4NPC1RAB9ASMN1; SMN2
Hydrochloric Acid SCHEMBL5330503 0.69 SLC2A1 (0.46) CA1CA2CA12CA5ACA9

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
WO-2007052831-A1 PREVENTIVES/REMEDIES FOR URINARY DISTURBANCE TAKEDA PHARMACEUTICAL COMPANY LIMITED (JP) 2007-05-10 WO disclosed
WO-2007033032-A1 CYCLOPROPYL FUSED INDOLOBENZAZEPINE HCV NS5B INHIBITORS BRISTOL-MYERS SQUIBB COMPANY (US) 2007-03-22 WO disclosed